Tuesday, October 19, 2021
اُردُو نیوز Newspaper Live-TV(UK) Live-TV(PK)
اُردُو نیوز Newspaper
Live-TV(UK) Live-TV(PK)

Aduro's pancreatic cancer drug fails in mid-stage study

Aduro's pancreatic cancer drug fails in mid-stage study
May 16, 2016
NEW YORK – Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study. In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro's GVAX Pancreas, the company said on Monday. Aduro's shares fell 33 percent to $7.14 in premarket trading. –Reuters
تازہ ترین خبریں حاصل کرنے کے لیے فوری اطلاع کی اجازت دیں

آپ کسی بھی وقت دائیں طرف نیچے بیل آئیکن پر صرف ایک کلک کے ذریعے آسانی سے سبسکرائب کر سکتے ہیں۔